Alectinib is indicated for:
Population group: both men and women, only adults (18 years old or older)
Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
For this indication, competent medicine agencies globally authorize below treatments (click for details):